Nasdaq Stockholm Welcomes NextCell Pharma to Nasdaq First North Growth Market
Stockholm, July 22nd, 2020 – Nasdaq (Nasdaq: NDAQ) announces that the trading in NextCell Pharma’s shares (short name: NXTCL) will commence today on Nasdaq First North Growth Market. NextCell Pharma belongs to the Healthcare sector and is the 29th company to be admitted to trading on Nasdaq’s Nordic markets* in 2020.
NextCell Pharma is a Swedish biopharmaceutical company running two business areas with the same core – stem cells from the umbilical cord. NextCell focuses on research and development of novel stem cell therapies and operates a tissue establishment and primary biobank, and is also a classified healthcare provider.
”Our international network is increasing, and joining Nasdaq First North Growth Market can further facilitate NextCell’s visibility,” said Mathias Svahn, CEO, NextCell.
“The growing healthcare and biopharmaceutical industry is an important sector for the Nordic region, and we are happy to welcome NextCell Pharma to Nasdaq First North,” said Adam Kostyál, Head of European Listings, Nasdaq. “We congratulate NextCell Pharma on its listing and look forward to supporting the company on their continued growth journey.”
NextCell Pharma has appointed FCNA Sweden AB as Certified Adviser.
*Main markets and Nasdaq First North at Nasdaq Copenhagen, Nasdaq Helsinki, Nasdaq Iceland and Nasdaq Stockholm
About Nasdaq
Nasdaq (Nasdaq: NDAQ) is a global technology company serving the capital markets and other industries. Our diverse offering of data, analytics, software and services enables clients to optimize and execute their business vision with confidence. To learn more about the company, technology solutions and career opportunities, visit us on LinkedIn, on Twitter @Nasdaq, or at www.nasdaq.com.
Nasdaq Media Contact
Yan-yan Tong
+46 (0)734496683
yan-yan.tong@nasdaq.com
|